

Multiple Sclerosis (MS) Relapsing-Remitting Multiple Sclerosis (RRMS)

A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

Trial Status
Not Yet Recruiting

Trial Runs In
0 Countries

Trial Identifier
NCT07503340 2025-524164-37-00
BA45841

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The main purpose of this study is to evaluate the pharmacokinetics (PK) of ocrelizumab administered subcutaneously (SC) in children and adolescents aged 10 to <18 years with RRMS. The study consists of a 48-week treatment period, an Optional Ocrelizumab Extension (OOE) period of at least 48 weeks, and Safety Follow-up (SFU) for 104 weeks.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT07503340 2025-524164-37-00 BA45841
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=10 Years & <= 17 Years

Healthy Volunteers
No
